お知らせ • Feb 14
Cyanotech Corporation Files Form 15 Cyanotech Corporation has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock, par value of $0.02 per share under the Securities Exchange Act of 1934, as amended. お知らせ • Jul 11
Cyanotech Corporation, Annual General Meeting, Aug 21, 2025 Cyanotech Corporation, Annual General Meeting, Aug 21, 2025. Location: nutrex hawaii warehouse, 9006 utica avenue, california 91730, rancho cucamonga United States お知らせ • Aug 25
Cyanotech Corporation Announces CFO Changes Cyanotech Corporation announced that Felicia Ladin will remain as Chief Financial Officer until her retirement date of September 5, 2024, at which point Ms. Jennifer Rogerson, age 35, will become CFO, VP of Finance and Administration, and Treasurer. Ms. Rogerson has over fifteen years of experience in accounting, finance and operations. From July 2022 to May 2024, Ms. Rogerson worked at Mixhers, LLC, as CFO, Chief Operating Officer and VP of Finance, with her last position as Executive VP. From March 2014 to July 2022, Ms. Rogerson worked at BestCompany, formerly SkyRocket Media, in which she had positions of increasing responsibility including Controller, Director of Accounting and Human Resources, with her last position as VP of People and Finance. Ms. Rogerson received a Bachelor of Science degree in Accounting from Western Governors University. お知らせ • Aug 24
Cyanotech Corporation Announces Executive Changes Cyanotech Corporation announced that Felicia Ladin will remain as Treasurer until her retirement date of September 5, 2024, at which point Ms. Jennifer Rogerson will become Treasurer. Ms. Rogerson has over fifteen years of experience in accounting, finance and operations. From July 2022 to May 2024, Ms. Rogerson worked at Mixhers, LLC, as CFO, Chief Operating Officer and VP of Finance, with her last position as Executive VP. From March 2014 to July 2022, Ms. Rogerson worked at BestCompany, formerly SkyRocket Media, in which she had positions of increasing responsibility including Controller, Director of Accounting and Human Resources, with her last position as VP of People and Finance. Ms. Rogerson received a Bachelor of Science degree in Accounting from Western Governors University. お知らせ • Jul 01
Cyanotech Corporation, Annual General Meeting, Aug 22, 2024 Cyanotech Corporation, Annual General Meeting, Aug 22, 2024. Location: 9006 utica avenue, california, 91730, rancho cucamonga United States お知らせ • Apr 10
The Nasdaq Stock Market to Delist the Common Stock of Cyanotech The Nasdaq Stock Market announced on April 08, 2024 that it will delist the common stock of Cyanotech Corporation. Cyanotech Corporation’s securities were suspended on February 20, 2024, and have not traded on Nasdaq since that time. お知らせ • Feb 21
Cyanotech Corporation(NasdaqCM:CYAN) dropped from NASDAQ Composite Index Cyanotech Corporation has been dropped from NASDAQ Composite Index. New Risk • Feb 15
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$552k free cash flow). Earnings have declined by 13% per year over the past 5 years. Market cap is less than US$10m (US$3.94m market cap). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (9.8% increase in shares outstanding). お知らせ • Feb 15
Cyanotech Receives Notification Letter from The Nasdaq Stock Market LLC Regarding Not Regains Compliance with the Bid Price Rule and Not Eligible for Second 180-Day Period On August 10, 2023, Cyanotech Corporation (the ‘Company’) received a notification letter (the ‘Notice’) from the Listing Qualifications Department (the ‘Staff’) of The Nasdaq Stock Market LLC (‘Nasdaq’) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on Nasdaq under Nasdaq Listing Rule 5550(a)(2) (‘Bid Price Rule’). The Notice provided that, in accordance with Nasdaq Listing Rule 5810(c)(3)(A) (the Compliance Period Rule), the Company has an initial period of 180 calendar days from the date of the Notice, or until February 6, 2024 (the ‘Compliance Date’), to regain compliance with the Bid Price Rule. If the Company is not in compliance with the Bid Price Rule by the Compliance Date, the Company may qualify for a second 180 calendar day compliance period, provided it meets the continued listing requirements for the market value of publicly held shares and all other applicable requirements for initial listing on Nasdaq (except for the Bid Price Rule). If the Company does not qualify for or fails to regain compliance during the second compliance period, then the Staff will provide written notification to the Company that its common stock will be subject to delisting. On February 8, 2024, the Company received a notification letter from the Staff that the Company has not regained compliance with the Bid Price Rule and is not eligible for a second 180-day period. Nasdaq has determined that the Company’s securities will be scheduled for delisting from Nasdaq and will be suspended at the opening of business on February 20, 2024, and a Form 25-NSE will be filed by Nasdaq with the Securities and Exchange Commission to remove the Company’s common stock securities from listing and registration on Nasdaq. The Company expects that its common stock will be eligible to be traded over-the-counter, however, no assurance can be given that trading of the Company’s common stock will be commenced or maintained on an over-the-counter markets or any other quotation medium. New Risk • Feb 11
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$552k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$552k free cash flow). Earnings have declined by 13% per year over the past 5 years. Market cap is less than US$10m (US$3.93m market cap). Minor Risk Shareholders have been diluted in the past year (9.8% increase in shares outstanding). Reported Earnings • Feb 09
Third quarter 2024 earnings released: US$0.16 loss per share (vs US$0.095 loss in 3Q 2023) Third quarter 2024 results: US$0.16 loss per share (further deteriorated from US$0.095 loss in 3Q 2023). Revenue: US$5.58m (down 5.2% from 3Q 2023). Net loss: US$1.02m (loss widened 71% from 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 63 percentage points per year, which is a significant difference in performance. Reported Earnings • Nov 10
Second quarter 2024 earnings released: US$0.13 loss per share (vs US$0.15 loss in 2Q 2023) Second quarter 2024 results: US$0.13 loss per share (improved from US$0.15 loss in 2Q 2023). Revenue: US$6.37m (up 23% from 2Q 2023). Net loss: US$797.0k (loss narrowed 15% from 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 64 percentage points per year, which is a significant difference in performance. Reported Earnings • Aug 13
First quarter 2024 earnings released: US$0.22 loss per share (vs US$0.076 loss in 1Q 2023) First quarter 2024 results: US$0.22 loss per share (further deteriorated from US$0.076 loss in 1Q 2023). Revenue: US$5.15m (down 23% from 1Q 2023). Net loss: US$1.37m (loss widened 190% from 1Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 59 percentage points per year, which is a significant difference in performance. お知らせ • Aug 12
Cyanotech Receives Notification Letter from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for its Common Stock On August 10, 2023, Cyanotech Corporation (the ‘Company’) received a notification letter (the ‘Notice’) from the Listing Qualifications Department (the ‘Staff’) of The Nasdaq Stock Market LLC (‘Nasdaq’) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5550(a)(2) (‘Bid Price Rule’). The Notice provided that, in accordance with the Nasdaq Listing Rule 5810(c)(3)(A) (the Compliance Period Rule), the Company has an initial period of 180 calendar days from the date of the Notice, or until February 6, 2024 (the ‘Compliance Date’), to regain compliance with the Bid Price Rule. If, at any time before the Compliance Date, the bid price for the Company’s common stock closes at $1.00 or more for a minimum of 10 consecutive business days, the Staff will provide written notification to the Company that it has regained compliance with the Bid Price Rule, unless the Staff exercises its discretion to extend this 10-day period pursuant to Nasdaq Listing Rule 5810(c)(3)(H). If the Company is not in compliance with the Bid Price Rule by the Compliance Date, the Company may qualify for a second 180 calendar day compliance period, provided it meets the continued listing requirements for the market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq (except for the Bid Price Rule). If the Company does not qualify for or fails to regain compliance during the second compliance period, then the Staff will provide written notification to the Company that its common stock will be subject to delisting. At that time, the Company may appeal the Staff’s delisting determination to the Nasdaq Hearings Panel. However, there can be no assurance that, if the Company receives a delisting notice and appeals the delisting determination, such an appeal would be successful. The Company will continue to monitor the closing bid price of its common stock. There can be no assurance that the Company will regain compliance with the Bid Price Rule during the 180-day compliance period, secure a second period of 180 days to regain compliance or maintain compliance with the other Nasdaq listing requirements. お知らせ • Aug 02
Cyanotech Corporation Appoints Collette Kakuk as Chief Strategic and Commercial Officer Cyanotech Corporation announced the appointment of Collette Kakuk as Chief Strategic and Commercial Officer. Ms. Kakuk brings an impressive background in business development, strategy, and marketing to add significant value to Cyanotech’s growing stable of products. Her industry experience, combined with a passionate drive for sustainable and authentic product sourcing, makes her an ideal addition to Cyanotech’s executive team. お知らせ • Jul 15
Cyanotech Corporation, Annual General Meeting, Aug 24, 2023 Cyanotech Corporation, Annual General Meeting, Aug 24, 2023, at 15:00 Hawaiian Standard. Location: Cyanotech Innovation Center, 73-4185 Unaloha Point Drive Kailua-Kona, Hawaii USA, 96740 Kailua Kona Hawaii United States Agenda: To consider and to elect the five director nominees named in the Proxy Statement to serve until the next Annual Meeting of Stockholders and until their successors are duly elected and qualified ; to consider and to hold an advisory vote on the compensation of company's Named Executive Officers ; to consider and to ratify the selection of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending March 31, 2024; and to consider other matters. New Risk • Jun 29
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (US$5.07m market cap). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change). Reported Earnings • Jun 28
Full year 2023 earnings released: US$0.55 loss per share (vs US$0.35 profit in FY 2022) Full year 2023 results: US$0.55 loss per share (down from US$0.35 profit in FY 2022). Revenue: US$23.2m (down 36% from FY 2022). Net loss: US$3.44m (down 260% from profit in FY 2022). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has only fallen by 31% per year, which means it has not declined as severely as earnings. お知らせ • May 09
Cyanotech Receives a Notification Letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC Regarding Bid Price Rule On May 2, 2023, Cyanotech Corporation received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that, for the last 30 consecutive business days, the bid price for the Company's common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5550(a)(2). The Notice provided that, in accordance with the Nasdaq Listing Rule 5810(c)(3)(A) (the Compliance Period Rule), the Company has an initial period of 180 calendar days from the date of the Notice, or until October 30, 2023 (the Compliance Date"), to regain compliance with the Bid Price Rule. If, at any time before the Compliance Date, the bid price for the Company's common stock closes at $1.00 or more for a minimum of 10 consecutive business days, the Staff will provide written notification to the Company that it has regained compliance with the Bid Price Rule, unless the Staff exercises its discretion to extend this 10-day period pursuant to Nasdaq Listing Rule 5810(c)(3)(H). If the Company is not in compliance with the Bid Price Rule by the Compliance Date, the Company may qualify for a second 180 calendar day compliance period, provided it meets the continued listing requirements for the market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq (except for the Bid Price Rule). If the Company does not qualify for or fails to regain compliance during the second compliance period, then the Staff will provide written notification to the Company that its common stock will be subject to delisting. At that time, the Company may appeal the Staff's delisting determination to the Nasdaq Hearings Panel. However, there can be no assurance that, if the Company receives a delisting notice and appeals the delisting determination, such an appeal would be successful. The Company will continue to monitor the closing bid price of its common stock. There can be no assurance that the Company will regain compliance with the Bid Price Rule during the 180-day compliance period, secure a second period of 180 days to regain compliance or maintain compliance with the other Nasdaq listing requirements. Reported Earnings • Feb 10
Third quarter 2023 earnings released: US$0.095 loss per share (vs US$0.062 profit in 3Q 2022) Third quarter 2023 results: US$0.095 loss per share (down from US$0.062 profit in 3Q 2022). Revenue: US$5.89m (down 38% from 3Q 2022). Net loss: US$598.0k (down 255% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. Reported Earnings • Nov 10
Second quarter 2023 earnings released: US$0.15 loss per share (vs US$0.16 profit in 2Q 2022) Second quarter 2023 results: US$0.15 loss per share (down from US$0.16 profit in 2Q 2022). Revenue: US$5.18m (down 45% from 2Q 2022). Net loss: US$940.0k (down 197% from profit in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Oct 04
Investor sentiment improved over the past week After last week's 16% share price gain to US$2.29, the stock trades at a trailing P/E ratio of 12.2x. Average trailing P/E is 15x in the Personal Products industry in the US. Total loss to shareholders of 1.3% over the past three years. Valuation Update With 7 Day Price Move • Aug 17
Investor sentiment deteriorated over the past week After last week's 19% share price decline to US$2.68, the stock trades at a trailing P/E ratio of 14.3x. Average trailing P/E is 20x in the Personal Products industry in the US. Total returns to shareholders of 7.2% over the past three years. Reported Earnings • Aug 11
First quarter 2023 earnings released: US$0.076 loss per share (vs US$0.085 profit in 1Q 2022) First quarter 2023 results: US$0.076 loss per share (down from US$0.085 profit in 1Q 2022). Revenue: US$6.72m (down 25% from 1Q 2022). Net loss: US$472.0k (down 191% from profit in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 95% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. お知らせ • Jul 19
Cyanotech Corporation, Annual General Meeting, Aug 25, 2022 Cyanotech Corporation, Annual General Meeting, Aug 25, 2022, at 15:00 Pacific Daylight. Location: Four Points by Sheraton Ontario-Rancho Cucamonga, California California United States Agenda: To elect the six director nominees named in the Proxy Statement to serve until the next Annual Meeting of Stockholders and until their successors are duly elected and qualified; to ratify the selection of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending March 31, 2023; and to transact other business as may properly come before the meeting or any adjournment thereof. Reported Earnings • Jun 23
Full year 2022 earnings released: EPS: US$0.35 (vs US$0.15 in FY 2021) Full year 2022 results: EPS: US$0.35 (up from US$0.15 in FY 2021). Revenue: US$36.0m (up 11% from FY 2021). Net income: US$2.15m (up 134% from FY 2021). Profit margin: 6.0% (up from 2.8% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 114% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Board Change • Apr 27
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. Independent Director Angela McElwee was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 12
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: US$0.062 (down from US$0.14 in 3Q 2021). Revenue: US$9.46m (up 35% from 3Q 2021). Net income: US$386.0k (down 53% from 3Q 2021). Profit margin: 4.1% (down from 12% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 118% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Recent Insider Transactions • Dec 04
Independent Chairman of the Board recently bought US$126k worth of stock On the 30th of November, Michael Davis bought around 36k shares on-market at roughly US$3.51 per share. This was the largest purchase by an insider in the last 3 months. This was Michael's only on-market trade for the last 12 months. Reported Earnings • Nov 12
Second quarter 2022 earnings released: EPS US$0.16 (vs US$0.026 in 2Q 2021) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2022 results: Revenue: US$9.42m (up 9.9% from 2Q 2021). Net income: US$970.0k (up US$815.0k from 2Q 2021). Profit margin: 10% (up from 1.8% in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 113% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Reported Earnings • Aug 12
First quarter 2022 earnings released: EPS US$0.085 (vs US$0.023 in 1Q 2021) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: US$8.96m (up 22% from 1Q 2021). Net income: US$520.0k (up 277% from 1Q 2021). Profit margin: 5.8% (up from 1.9% in 1Q 2021). Over the last 3 years on average, earnings per share has increased by 96% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Reported Earnings • Jun 27
Full year 2021 earnings released: EPS US$0.15 (vs US$0.065 in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: US$32.3m (up 1.4% from FY 2020). Net income: US$920.0k (up 138% from FY 2020). Profit margin: 2.8% (up from 1.2% in FY 2020). Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Mar 27
Investor sentiment deteriorated over the past week After last week's 17% share price decline to US$3.17, the stock trades at a trailing P/E ratio of 15.4x. Average trailing P/E is 17x in the Personal Products industry in the US. Total loss to shareholders of 38% over the past three years. Valuation Update With 7 Day Price Move • Mar 12
Investor sentiment improved over the past week After last week's 16% share price gain to US$4.12, the stock is trading at a trailing P/E ratio of 20x, up from the previous P/E ratio of 17.3x. This compares to an average P/E of 20x in the Personal Products industry in the US. Total return to shareholders over the past three years is a loss of 22%. Is New 90 Day High Low • Mar 12
New 90-day high: US$4.12 The company is up 33% from its price of US$3.09 on 11 December 2020. The American market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 16% over the same period. Reported Earnings • Feb 12
Third quarter 2021 earnings released: EPS US$0.14 (vs US$0.029 in 3Q 2020) The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2021 results: Revenue: US$6.99m (down 6.9% from 3Q 2020). Net income: US$827.0k (up 384% from 3Q 2020). Profit margin: 12% (up from 2.3% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Feb 11
New 90-day high: US$3.92 The company is up 40% from its price of US$2.80 on 12 November 2020. The American market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 19% over the same period. Is New 90 Day High Low • Jan 22
New 90-day high: US$3.40 The company is up 21% from its price of US$2.82 on 23 October 2020. The American market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 19% over the same period. Is New 90 Day High Low • Jan 05
New 90-day high: US$3.22 The company is up 26% from its price of US$2.56 on 06 October 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 22% over the same period. Is New 90 Day High Low • Dec 10
New 90-day high: US$3.17 The company is up 2.0% from its price of US$3.12 on 10 September 2020. The American market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 16% over the same period. Recent Insider Transactions • Nov 28
Independent Director recently sold US$108k worth of stock On the 23rd of November, Walter Menzel sold around 42k shares on-market at roughly US$2.58 per share. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought US$103k more than they sold in the last 12 months. Reported Earnings • Nov 13
Second quarter 2021 earnings released: EPS US$0.026 The company reported a soft second quarter result with weaker earnings and profit margins, although revenues were improved. Second quarter 2021 results: Revenue: US$8.57m (up 12% from 2Q 2020). Net income: US$155.0k (down 32% from 2Q 2020). Profit margin: 1.8% (down from 3.0% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 15% per year, which means it is performing significantly worse than earnings. Valuation Update With 7 Day Price Move • Oct 16
Market bids up stock over the past week After last week's 20% share price gain to US$3.05, the stock is trading at a trailing P/E ratio of 27.7x, up from the previous P/E ratio of 23.2x. This compares to an average P/E of 20x in the Personal Products industry in the US. Total return to shareholders over the past three years is a loss of 38%. Valuation Update With 7 Day Price Move • Oct 12
Market bids up stock over the past week After last week's 23% share price gain to US$3.02, the stock is trading at a trailing P/E ratio of 27.5x, up from the previous P/E ratio of 22.4x. This compares to an average P/E of 21x in the Personal Products industry in the US. Total return to shareholders over the past three years is a loss of 36%. お知らせ • Oct 03
Cyanotech Corporation Launches Bioastin Cyanotech Corporation announced its launch of BioAstin Hawaiian Astaxanthin in a new delivery form, water dispersible powder, available in both 1% and 2% concentrations. The Nation’s #1 brand of Astaxanthin, BioAstin, is now offering their new water dispersible powder to the bulk ingredients market worldwide. BioAstin Hawaiian Astaxanthin is a powerful antioxidant derived from natural Haematococcus pluvialis microalgae grown on the Kona Coast of the Big Island of Hawaii. Cyanotech is the most vertically integrated producer of naturally grown Astaxanthin, and its new powder is no exception. From pond to powder, Cyanotech offers the world’s first and only water dispersible powder produced all in one location ensuring the highest possible quality. Astaxanthin is a superior nutrient for formulations and condition specific products as it has been clinically studied to help support cardiovascular, eye, immune, skin, and joint health, as well as recovery from exercise. BioAstin Hawaiian Astaxanthin Water Dispersible Powder is free-flowing and it’s dispersible in either hot or cold water. It’s ready to be incorporated into drink powder mixes, ready to drink beverages, teas, fruit juices, as well as carbonated beverages. The flavor of the powder is neutral and similar to other plant-based proteins but can be blended with various flavor profiles to reach the desired taste. Additionally, Cyanotech’s astaxanthin powder offers another alternative for consumers that do not like to swallow supplements. BioAstin 1% and 2% powders are certified Gluten Free and Kosher, with other certifications pending (Halal, Vegan, I-Gen, Certified for Sport and Detox Project).